|
|
Dariohealth Corp (NASDAQ: DRIO) |
|
Price: $0.6289
$0.03 
4.799%
|
| Day's High:
| $0.65
| Week Perf:
| -1.75 %
|
| Day's Low: |
$ 0.59 |
30 Day Perf: |
-29.34 % |
| Volume (M): |
97 |
52 Wk High: |
$ 2.60 |
| Volume (M$): |
$ 61 |
52 Wk Avg: |
$1.17 |
| Open: |
$0.60 |
52 Wk Low: |
$0.10 |
|
|
| Market Capitalization (Millions $) |
25 |
| Shares
Outstanding (Millions) |
40 |
| Employees |
152 |
| Revenues (TTM) (Millions $) |
22 |
| Net Income (TTM) (Millions $) |
47 |
| Cash Flow (TTM) (Millions $) |
-28 |
| Capital Exp. (TTM) (Millions $) |
0 |
Dariohealth Corp
DarioHealth Corp is a global digital therapeutics company that focuses on providing individuals with chronic conditions access to remote monitoring and management tools. The company offers a mobile platform that allows patients to monitor and manage their health in real-time. Their flagship product, the Dario blood glucose monitoring system, is designed for people with diabetes and enables them to track their blood sugar levels, medication intake, and lifestyle factors.
DarioHealth's platform also includes coaching, education, and support features to empower individuals in self-managing their conditions. By leveraging technology and data analytics, the company aims to improve health outcomes and reduce the burden on healthcare systems. Additionally, DarioHealth offers its digital therapeutics platform to employers and health plans to support their wellness initiatives and lower healthcare costs.
With a user-friendly interface and connectivity to various health devices, DarioHealth provides a convenient and comprehensive solution for individuals with chronic conditions to stay engaged in their healthcare journey. The company operates globally, serving customers in North America, Europe, and Asia-Pacific regions.
Company Address: 322 W. 57th St. #33B New York 10019 NY
Company Phone Number: 770-6377 Stock Exchange / Ticker: NASDAQ DRIO
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Dariohealth Corp
Dariohealth Corp, a prominent player in the medical equipment and supplies sector, recently announced its financial results for the most recent fiscal period. These results have come as a surprise to many investors and analysts, as they depict a significant decline in various key financial indicators.
First and foremost, the company's earnings per share (EPS) plummeted by a staggering 55.56% to $0.20 per share compared to $0.45 a year prior. This is a concerning drop, indicating a decline in the company's profitability and performance. Similarly, the net profit also took a hit, decreasing by 51.34% from $0.41 per share in the prior reporting period.
|
| Dariohealth Corp
Dariohealth Corp, a medical equipment and supplies company, recently released its financial results for the fourth quarter of 2023. The company reported a 21.67% increase in income, with earnings of $0.41 per share compared to $0.34 per share a year ago. However, profits fell by -16.13% from $0.49 per share in the prior reporting period. The company also experienced a significant drop in revenue, with a decrease of -52.077% to $4.23 million from $8.84 million in the same reporting period last year. However, sequentially, revenue surged by 62.222% from $2.61 million.
Despite the decline in revenue, Dariohealth Corp managed to increase its bottom-line, reporting net earnings of $14.285 million in the fourth quarter of 2023, a 17.42% increase from the net earnings of $12.166 million reported in the same period a year ago. The company also highlighted its improving profit margins, with a net margin of 337.39% and an operating margin of 335.73% in the fourth quarter of 2023.
|
| Dariohealth Corp
Dariohealth Corp has faced some challenges in the July to September 2023 period, with a decline in income, profits, and revenue compared to the previous year. The company's income fell by -23.44% to $0.49 per share, while profits fell by -15.52% to $0.58 per share. Revenue also took a significant hit, falling by -60.484% to $2.61 million.
This deterioration in the company's top-line is in contrast to the rest of the Medical Equipment & Supplies industry, which experienced a revenue improvement during the same reporting period. However, despite these challenges, Dariohealth Corp is determined to bounce back.
|
| Dariohealth Corp
As an experienced financial journalist, I have closely analyzed the financial results of Dariohealth Corp for the second quarter of 2023. Despite an impressive revenue growth of 19.355% to $6.07 million, the company's profits deteriorated, with income falling by -21.62% to $0.58 per share. This downward trend is concerning for investors and indicates potential challenges that Dariohealth Corp needs to address.
Compared to its industry contemporaries in the Medical Equipment & Supplies sector, Dariohealth Corp has outperformed with its top-line growth. While the industry only expressed a 4.48% revenue growth during the same period, Dariohealth Corp managed to achieve double-digit growth. However, this success in generating revenue did not translate into increased earnings as expected.
|
| Dariohealth Corp
Investors and analysts should take note of the concerning developments in Dariohealth Corp's receivables turnover ratio, indicating difficulties in collecting its outstanding accounts receivable from corporate clients. The ratio has lowered to 6.54, which is below the company average, and a distinct sign of a worsening business environment.
Furthermore, average receivable collection periods for the company saw a decrease to 56 days in the Mar 31 2023 quarter, compared to the preceding quarter, Dec 31 2022, where it stood at 62 days. This phenomenon suggests that the company is finding it increasingly challenging to obtain payments from its clients.
Unfortunately, the situation doesn't seem to be isolated to Dariohealth Corp, as other healthcare companies have higher receivables turnover ratios, indicating overall better performance in terms of collecting payment on outstanding accounts.
|
| Per Share |
Current |
| Earnings (TTM) |
0.94 $ |
| Revenues (TTM) |
0.55 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.41 $
|
| Book Value |
1.45 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
0.94 $
|
| Revenues (TTM) |
0.55 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.41 $
|
| Book Value |
1.45 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
1.32%